Unlearn.AI
Unlearn.AI uses AI-generated digital twins to make clinical trials faster and more efficient by predicting patient outcomes and reducing required sample sizes. The company provides a B2B SaaS platform that applies machine learning, deep learning, and biostatistics to create prognostic digital twins and implement TwinRCTs that integrate historical data into randomized trials. Its solution is used by pharmaceutical and biotech sponsors across therapeutic areas such as neuroscience, immunology, and metabolic disease and aligns with EMA qualification and FDA guidance. Unlearn.AI’s platform supports trial simulation, responder identification, and more precise treatment-effect estimation to de-risk trial design and accelerate development timelines.
Unlearn.AI
Unlearn.AI uses AI-generated digital twins to make clinical trials faster and more efficient by predicting patient outcomes and reducing required sample sizes. The company provides a B2B SaaS platform that applies machine learning, deep learning, and biostatistics to create prognostic digital twins and implement TwinRCTs that integrate historical data into randomized trials. Its solution is used by pharmaceutical and biotech sponsors across therapeutic areas such as neuroscience, immunology, and metabolic disease and aligns with EMA qualification and FDA guidance. Unlearn.AI’s platform supports trial simulation, responder identification, and more precise treatment-effect estimation to de-risk trial design and accelerate development timelines.
